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ERK8 (MAPK15) is a large MAP kinase already implicated in
the regulationof the functions of different nuclear receptors and
in cellular proliferation and transformation. Here, we identify
ERR as a novel ERK8-interacting protein. As a consequence of
such interaction, ERK8 inducesCRM1-dependent translocation
of ERR to the cytoplasm and inhibits its transcriptional activ-
ity. Also,we identify inERK8 twoLXXLLmotifs, typical of agonist-
boundnuclear receptor corepressors, as necessary features for this
MAPkinase to interactwithERRand to regulate its cellular local-
ization and transcriptional activity. Ultimately, we demonstrate
thatERK8 is able to counteract, in immortalizedhumanmammary
cells, ERR activation inducedby theEGF receptor pathway, often
deregulated in breast cancer. Altogether, these results reveal a
novel function forERK8as abona fideERR corepressor, involved
in control of its cellular localization by nuclear exclusion, and sug-
gest a key role for thisMAP kinase in the regulation of the biolog-
ical activities of this nuclear receptor.
Mitogen-activated protein (MAP) kinases are a family of pro-
line-directed serine/threonine kinases expressed in all eukary-
otic cells, from yeast to human, and involved in key signaling
pathways regulating cell proliferation, differentiation, apopto-
sis, and stress response (1, 2). ERK8 is the last identified mem-
ber of theMAP kinase family. Along with a typical MAP kinase
domain, it possesses a peculiarly long, unique C-terminal
domain (3). Its activity can be modulated by serum, DNA dam-
age, and activated human oncogenes such as BCR/ABL and
RET/PTC3 (3–5). Still, although ERK8 has the classical signa-
ture Thr-Glu-Tyr activation motif of signal-dependent kinases
such as ERK1, ERK2, and ERK5, it is not significantly activated
by many extracellular stimuli that typically impinge on MAP
kinases, and no MAP kinase kinase (MAPKK) has been identi-
fied that regulates its activity (6).2 Interestingly, ERK8 has been
recently involved in the transformation of human colon cancer
cells (7) and in the maintenance of genomic integrity, by inhib-
iting proliferating cell nuclear antigen (PCNA) degradation (8).
Recent data have also shown the ability of ERK8 to reduce the
activity of nuclear receptors such as androgen and glucocorti-
coid receptors (9, 10).Moreover, ERK8 strongly enhances ubiq-
uitin-dependent degradation of estrogen receptor  (ER),3
and loss of its expression has been correlated to breast cancer
progression and increased ER levels in mammary tumors (9).
However, its targets and downstream effectors still remain
almost completely unknown. Likewise, its biological functions
have yet to be unraveled.
ERR (NR3B1) was the first “orphan” nuclear receptor to be
identified, on the basis of its similarity to ER (11). It is a key
regulator of mitochondrial biogenesis (12), energy metabolism
(13), and bone formation and maintenance (14). ERR binds
to DNA and regulates transcription through specific ERR
response elements (ERREs), also named SF-1 response ele-
ments (SFREs), as well as through classical estrogen receptor
response elements (EREs) (15, 16). The natural ligand of ERs,
17-estradiol (E2), does not bind to ERR (17). However, based
on the ability of this steroid receptor to compete with ER in the
binding to EREs and to heterodimerize with it, ERRmay play
a role in the response of some genes to estrogen, thus leading to
a possible overlap between ERR and ERs transcriptional tar-
gets (15).
No endogenous ligand of ERR has been reported to date.
This observation, along with structural data showing that the
putative ligand-binding pocket of ERR is already locked in an
agonist-bound conformation, led to considering ERR as a
“true orphan,” constitutively active, nuclear receptor (18).
However, despite the lack of natural ligands, the transcriptional
activity of ERR can be finely modulated by coregulatory “pro-
teic ligands” such as coactivators and corepressors (19). As a
matter of fact, such coregulators assume a huge importance in
the modulation of orphan nuclear receptors, due to the lack of
regulation by natural ligands. Indeed, the regulation of ERR
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receptor- coactivator-1 (PGC1), a powerful coactivator
that controls its role in cellular functions such as oxidative
phosphorylation, mitochondrial biogenesis, and respiration
(20, 21).
Evidence of ERR roles in humanmalignancies, especially in
breast cancer, is rapidly accumulating (22–26). Moreover, the
EGF receptor and ErbB2 signaling pathways regulate ERR
transcriptional activity, leading to its hyperphosphorylation
and enhancing its DNA binding (27, 28). Therefore the possi-
bility to modulate ERR activity is currently regarded as a val-
uable approach to target breast cancer as well as other aggres-
sive human malignancies (23–25).
EXPERIMENTAL PROCEDURES
Antibodies and Western Blot Analysis—The following pri-
mary antibodies were used for Western blot experiments: HA
(Covance), Lamin A/C, IB, ERK2, PGC1 (Santa Cruz Bio-
technology), -actin (Sigma), and ERK8 (Kinasource). HA
(Santa Cruz Biotechnology) was used as the primary antibody
for confocal microscopy experiments. The following primary
antibodieswere used forWestern blot and confocalmicroscopy
experiments: ERR (Epitomics) and ERK8 (custom prepara-
tion). AU1 (Covance) was used as the primary antibody for
Western blot, immunoprecipitation, and confocal microscopy
experiments. Rabbit preimmune serum (Santa Cruz Biotech-
nology) was used as a negative control in immunoprecipitation
experiments. The following secondary antibodies were used for
Western blot experiments: HRP-conjugated anti-mouse IgG,
HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology),
and HRP-conjugated anti-sheep IgG (Calbiochem). For West-
ern blot analysis, proteins derived from total lysates, immuno-
precipitations, or affinity precipitations were loaded on SDS-
PAGE, transferred to Immobilon-P PVDF membrane
(Millipore), probed with appropriate antibodies, and revealed
by enhanced chemiluminescence detection (ECL Plus; GE
Healthcare). Bacterially expressed proteins were loaded on
SDS-PAGE gels, stained with SimplyBlue SafeStain (Invitro-
gen), and revealed using the Odyssey Infrared Imaging System
(Li-Cor Biosciences).
Expression Vectors—For two-hybrid screening, a DNA frag-
ment encoding for the C-terminal domain of ERK8 from amino
acids 267 to 544 was cloned in the pGBKT7 vector (Clontech).
For bacterial expression of the C-terminal domain of the ERR
protein, the pGEX-4T3-ERR_C-terminal plasmid was pre-
pared by cloning a DNA fragment encoding for the murine
ERR C-terminal domain, specifically contained in the two-
hybrid clone, in the pGEX-4T3 vector. The pCEFL HA ERK8
expression vector has been previously described (4). The
pCEFL EGFP ERK8 expression vector was generated by sub-
cloning the ERK8 cDNA, obtained by restriction enzyme diges-
tion from pCEFL HA ERK8, into the pCEFL EGFP vector. The
pCEFL HA ERK8 3LA1, pCEFL HA ERK8 3LA2, and pCEFL
HA ERK8 3LA1–2 expression vectors were generated with the
QuikChange site-directed mutagenesis kit (Stratagene), using
pCEFLHA ERK8 as a template. The pCEFL AU1 ERR expres-
sion vector was generated by subcloning the ERR cDNA,
obtained by PCR from the pBlueScript ERR vector (Clone ID
30336569) from the IMAGE Consortium, into the pCEFL AU1
vector. The pCEFLGSTERR expression vector was generated
by subcloning the ERR cDNA, obtained by restriction enzyme
digestion from pCEFL AU1 ERR, into the pCEFL GST vector.
The pCDNA3 HA JNK expression vector has been previously
described (29). The pCEFL AU1 ERR and pCEFL AU1 ERR
expression vectors were generated by subcloning the ERR and
ERR cDNAs, obtained by PCR from pBlueScriptR ERR
(Clone ID 30344716) and pENTR223.1 ERR (Clone ID
100015441) from Open Biosystems, into the pCEFL AU1 vec-
tor. The ERRE_Luc firefly luciferase reporter vector is a kind
gift from J. M. Vanacker (16). The pcDNA4 PGC1 (Addgene
plasmid 10974), pBABE5 EGFR L858R (Addgene plasmid
11012), and pBABE5 EGFR D770_N771 insNPG (Addgene
plasmid 11016) expression vectors were obtained from Add-
gene (addgene.org). The identity and integrity of all vectors was
confirmed by DNA sequencing.
Cell Culture and Transfection—HEK293T and HeLa cells
were maintained in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum, 2mM L-glutamine, and
100 units/ml of penicillin-streptomycin at 37 °C in an atmo-
sphere of 5% CO2/air. MCF10A cells were maintained in
DMEM/Ham’s F-12 medium supplemented with 5% horse
serum, 2 mM L-glutamine, 100 units/ml of penicillin-strepto-
mycin, 10 ng/ml of epidermal growth factor (EGF), 0.5g/ml of
hydrocortisone, 100 ng/ml of cholera toxin, and 10 g/ml of
insulin at 37 °C in an atmosphere of 5% CO2/air. To generate
the MCF10A cell lines stably expressing EGFP and HA ERK8,
MCF10A cells were transfected with the pCEFL EGFP and
pCEFL HA ERK8 expression vectors, respectively, and sub-
jected to selection with G-418 sulfate for 2 weeks.
For Western blot and immunoprecipitation experiments,
1 106 cells were seeded in 6-cm plates and transfected with 1
g of the different expression vectors using Lipofectamine LTX
(Invitrogen). For luciferase assays, 1 105 cells were seeded in
12-well plates and transfected with 50 to 100 ng of the ERRE_
Luc firefly luciferase reporter vector and 500 ng of the different
expression vectors using Polyfect (Qiagen) for HeLa cells and
Lipofectamine LTX (Invitrogen) for MCF10A cells. All experi-
ments were performed 24 h after transfection. For confocal
microscopy experiments, 2.5 104 cells were seeded on cover-
slips placed onto 12-well plates. For 293T cells, coverslips were
pre-coated with polylysine (Sigma). Each sample was trans-
fected with 200 to 500 ng of each plasmid using Lipofectamine
LTX (Invitrogen).
Yeast Two-hybrid Screening—To isolate potential ERK8
interacting proteins, we used a region comprising its C-termi-
nal 277 amino acids (amino acids 267–544) as a bait to perform
a yeast two-hybrid screening. The cDNAcorresponding to such
a region was cloned in the pGBKT7 plasmid (Clontech), in-
frame with the yeast GAL4 DNA-binding domain, by PCR
amplification followed by enzymatic digestion. Thanks to the
presence of a MYC epitope in the resulting fusion protein
(MYC-GAL4-ERK8 C-term), we confirmed the expression of
such a protein in yeast. Before starting the screening we also
confirmed that our bait was not able to activate, by itself, the
transcription of reporter genes. In addition, we confirmed that
our bait could not interact directly with the GAL4 transactiva-
tion domain contained in the plasmid employed to engineer the
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cDNA library used for the screening. In this regard, we used a
Clontech mouse brain cDNA library (Matchmaker GAL4 two-
hybrid system 3).
For the screening, we co-transformed 500g of the pGBKT7
ERK8_C-term bait and 1 mg of library DNA in yeast strain
PJ69-4A. Protein-protein interactions were assessed by streak-
ing transformants on selective medium lacking Leu, Trp, and
His with addition of 3–10 mM 3-aminotriazole. Potential inter-
actors were sequenced from the pACT2 plasmid by using the
Matchmaker 5 and Matchmaker 3 primers (Clontech).
Bacterial Expression of GST Fusion Proteins—The BL21 Lys
strain of Escherichia coli was transformed with the pGEX-4T3
vector alone or encoding for the mouse ERR C-terminal
fusion protein. Bacterially expressed GST and GST fusion pro-
tein were purified as previously described (30).
Immunofluorescence, Confocal Microscopy, Intensitometric
Analysis of Fluorescence, and Count of ERR-positive Nuclei—
Twenty-four hours after transfection, cells were washed with
PBS, then fixed with 4% paraformaldehyde in PBS for 20 min
and permeabilized and blocked with a solution of 0.075% sapo-
nin (Sigma) and 0.2% gelatin (Sigma) in PBS for 20 min. Cells
were incubated with appropriate primary antibodies for 1 h,
washed three times with PBS, incubated with appropriate Cy2-
conjugated andTRITC-conjugated secondary antibodies (Jack-
son ImmunoResearch Laboratories), and then washed again
three timeswith PBS.Nuclei were stainedwith a 15M solution
of 4,6-diamidino-2-phenylindole (DAPI) (Sigma) in PBS for 3
min. Coverslips were mounted in Fluorescence Mounting
Medium (Dako). Samples were visualized on a TSC SP5 confo-
cal microscope (Leica) adapted to an inverted LEICA DMI
6000CS microscope and equipped with an oil immersion Pla-
nApo 63 1.4 NA objective. Images were acquired using LAS
AF acquisition software (Leica). Intensitometric analysis of
fluorescence was performed using the Quantitation Module of
Volocity software (PerkinElmer Life Science). For the count
of ERR-positive nuclei, the total number of ERR-positive
cells and the number of cells with nuclear ERR staining were
determined in 20 random fields; the results were expressed as
percentages of the ratio between ERR-positive nuclei and
ERR-positive cells. In samples co-transfected with ERR and
ERK8, only cells expressing both proteins were considered.
Luciferase Assays—HeLa cells were transfected with 50 ng of
the ERRE_Luc firefly luciferase reporter vector and 500 ng of
different expression vectors (unless otherwise indicated).
MCF10A cells were transfected with 100 ng of the SFRE_Luc
firefly luciferase reporter vector and 500 ng of different expres-
sion vectors. Twenty-four hours after transfection, cells were
lysed in Passive Lysis Buffer (Promega) and luciferase activity in
the cellular lysates was assessed on a Glomax 20/20 lumino-
meter (Promega) using the Luciferase Assay System (Promega).
Results were normalized for total protein content. All luciferase
results represent the normalized average S.D. of at least two
independent transfections. All samples were read in triplicate.
Knock-down of Endogenous ERK8—ERK8-specific siRNA
(target sequence 5-TTGCTTGGAGGCTACTCCCAA-3)
and control non-silencing siRNA (target sequence 5-AATTC-
TCCGAACGTGTCACGT-5) were obtained from Qiagen.
HeLa cells were transfected with ERK8-specific or control
non-silencing siRNA at a final concentration of 5 nM using
HiPerFect (Qiagen), according to the manufacturer’s instruc-
tions. Samples were collected 48 h after transfection.
Expression Analysis of ERR Target Genes—Total RNA was
purified using TRIzol Reagent (Invitrogen). Reverse transcrip-
FIGURE 1. ERK8 and ERR interact both in vitro and in vivo. A, one positive
clone encoding for ERR was tested to be devoid of autoactivation. Yeast cells
were co-transformed with the pACT2 vector containing the ERR cDNA, with
pGBKT7 alone (left) or with pGBKT7 ERK8_C-term (right), and streaked on selec-
tive medium. B, in vitro GST pulldown. Bacterially expressed GST-tagged ERR
(lanes 3 and 4) or GST alone (lanes 1 and 2), immobilized on glutathione-Sephar-
ose Beads 4B, were incubated for 2 h at 4 °Cwith lysates of 293T cells transiently
transfectedwithacontrolvectororwithHA-ERK8, thenanalyzedbyWesternblot
(WB) with anti-ERK8 antibody (top). As additional negative controls, glutathione
beadsconjugatedwithGSTaloneorwithGSTERRwerealso loaded (lanes5and
6). 293T cellular lysates were analyzed byWestern blot with anti-ERK8 antibody
(middle) andbacterially expressedGSTandGSTERRwereanalyzedbyCoomas-
sie staining (bottom) for normalization purposes. C, in vivo GST pulldown. 293T
cellswereco-transfectedwithacontrol vectororwithAU1-ERR, in thepresence
or absence of EGFP-ERK8. Lysates (1 mg) were then immunoprecipitated with
anti-AU1 antibody (4 h at 4 °C) and blotted with anti-ERK8 antibody (top). For
normalizationpurposes of input samples, total cellular lysates (20g)were blot-
tedwith anti-ERK8 (middle) and anti-ERR (bottom) antibodies.
ERK8 as an ERR Corepressor
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tion was performed with the QuantiTect Reverse Transcription
Kit (Qiagen). Real time PCR (RT-PCR) was performed with the
FastStart SYBR Green Master Mix (Roche Applied Science) on a
Rotor-Gene 6000 RT-PCR system (Corbett Life Science). The fol-
lowing primer pairs were used: ERK8, 5-GGAGTTTGGGGAC-
CATCC-3 and 5-GCGTTCAGGTCAGTGTCC-3; ERK2,
5-GCCCATCTTTCCAGGGAAGCATTA-3 and 5-AGAGC-
TTTGGAGTCAGCATTTGGG-3; CYP11A1, 5-CGCTTTGC-
CTTTGAGTCCATCACTA-3 and 5-TCTTGGTCCTGAAC-
AGACGGAACA-3; CYP27A1, 5-TGGAGTGGACACGACA-
TCCAA-3 and 5-ATGTGGGCAAAGTCCTTGTGCT-3.
Subcellular Fractionation—Cytoplasmic and nuclear frac-
tions were obtained by the Subcellular Protein Fractionation
Kit (Thermo Scientific), according to the manufacturer’s
instructions.
RESULTS
ERK8 Interacts with ERR in Vitro and in Vivo—We carried
out a yeast-based two-hybrid screening to identify novel ERK8
interacting proteins. As ERK8 is characterized by a quite pecu-
liar, long C-terminal domain, we decided to use this domain as
bait for this screening. We chose to screen a mouse brain
library, based on the evidence that ERK8 is highly expressed in
the nervous system (3). Among the positive clones, we found
multiple clones encoding for ERR. One of these was con-
firmed to be devoid of autoactivation (Fig. 1A). Next, we per-
formed pulldown experiments using full-length, HA-tagged
ERK8 from a 293T cellular lysate and bacterially expressed,
GST-tagged C-terminal domain of ERR. As shown in Fig. 1B,
the ERR fragment corresponding to the clone identified by the
two-hybrid screening readily interacted, in vitro, with the ERK8
protein. To determine whether ERK8 is able to interact also in
vivowith ERR, we performed co-immunoprecipitation exper-
iments in 293T cells, co-transfecting EGFP-ERK8 with full-
length, AU1-tagged, human ERR. As shown in Fig. 1C, ERK8
evidently co-immunoprecipitated in vivo with ERR. Alto-
gether, these results indicate a physical interaction between
ERK8 and ERR.
ERK8 Promotes Re-localization of Nuclear ERR to the
Cytoplasm—To confirm the in vivo interaction of ERR and
ERK8, we next decided to investigate the cellular localization of
these two proteins. Information about ERK8 subcellular local-
ization is still limited. Therefore, we first sought to determine
its subcellular localization in 293T cells, our experimental
model. In these settings, ERK8wasmostly localized to the cyto-
plasm, whereas a much lower signal appeared in the nucleus
(Fig. 2A, left panels). In turn, in the same model, we confirmed
the already described (31, 32) predominantly nuclear localiza-
tion of ERR (Fig. 2B, left panels). To further support the afore-
mentioned evidence and obtain quantitative information about
the subcellular localization of ERK8 and ERR, we measured
fluorescence intensity in the nucleus and cytoplasm, as shown
in the representative images in the left panels of Fig. 2, A and B,
respectively. As expected, ERK8 was mainly cytoplasmic (Fig.
2A, right panel), whereas ERR was mostly nuclear (Fig. 2B,
right panel). Still, co-transfecting ERK8 and ERR, we observed
that they co-localized to the cytoplasm only in cells expressing
both proteins, whereas ERR maintained its nuclear localiza-
tion in cells not expressing ERK8 (Fig. 2C, left panels). As a
control, the overexpression of another MAP kinase, JNK,
together with ERR did not affect subcellular localization of
this nuclear receptor (Fig. 2D, left panels). As an additional
confirmation to these observations and to obtain quantitative
data, we counted the number of ERR-positive nuclei from
cells expressing only ERR or both ERR and ERK8. ERK8 co-
expression led to an80% reduction in the number of cellswith
ERR-positive nuclei (Fig. 2C, right panel). As a control, no
decrease in the number of cells with ERR-positive nuclei
occurred following JNK co-expression (Fig. 2D, right panel).
ERR, ERR, and ERR belong to the same subfamily of
nuclear receptors and share several features, such as the lack of
an endogenous ligand and the ability to bind the same DNA
consensus sequence (33). Nevertheless, co-expression with
ERK8 did not interfere with nuclear localization of ERR and
ERR, showing a clear difference in their behavior compared
with ERR (supplemental Fig. S1A). These observations there-
fore confirm our data showing a direct interaction between
ERR and ERK8 and strongly suggest a specific role for ERK8 in
selectively determining the subcellular localization of ERR.
ERK8 Re-localizes Nuclear ERR to the Cytoplasm with a
CRM1-dependentMechanism—The antifungal compound lep-
tomycin B (LMB) specifically blocks the nuclear export of pro-
teins by preventing their association with the CRM1 export
receptor (34). Indeed, the use of LMB already implicated this
karyopherin in the export of different nuclear receptors. One
such example is ER, whose nuclear export is inhibited by LMB
in breast cancer cell lines (35, 36).
As no information is yet available about ERK8 nucleo-
cytoplasmic transport, we first determined the behavior of
this protein upon LMB treatment in HeLa cells, often used
to investigate CRM1 activity. As described in Fig. 3A, left
FIGURE2.ERK8promotes re-localizationofERR to thecytoplasm.A, left panels, confocalmicroscopy images showing the localizationof ERK8, in293Tcells.
Cells were transfected with HA-ERK8 (300 ng), incubated with anti-ERK8 antibody, and labeled with Cy2-conjugated secondary antibody. A, right panel,
intensitometric analysis of ERK8 and DAPI fluorescence in the nuclear and cytoplasmic compartments of 293T cells; analysis was performed on the represen-
tative images in A, left panels. B, left panels, confocal microscopy images showing the localization of ERR in 293T cells. Cells were transfected with AU1-ERR
(300 ng), incubated with anti-AU1 antibody, and labeled with TRITC-conjugated secondary antibody. B, right panel, intensitometric analysis of ERR and DAPI
fluorescence in the nuclear and cytoplasmic compartments of 293T cells; analysis was performed on the representative images in B, left panels. C, left panels,
confocal microscopy images of 293T cells co-transfected with AU1-ERR (300 ng) and HA-ERK8 (300 ng), then incubated with anti-AU1 and anti-ERK8
antibodies and labeled with TRITC- and Cy2-conjugated secondary antibodies. C, right panel, decrease in the number of 293T cells with AU1-ERR-positive
nuclei in the presence of HA-ERK8. 293T cells were transfected and labeled as in C, left panels, then cells with AU1-ERR-positive nuclei were counted in 20
random fields. D, left panels, confocal microscopy images of 293T cells co-transfected with AU1-ERR (300 ng) and HA-JNK (300 ng), then incubated with
anti-ERR and anti-HA antibodies and labeledwith TRITC- and Cy2-conjugated secondary antibodies.D, right panel, the number of 293T cells with AU1-ERR-
positive nuclei is not affected by the presence of HA-JNK. 293T cells were transfected and labeled as in D, left panels, then cells with AU1-ERR-positive nuclei
were counted in 20 random fields. In all experiments involving the count of HA-ERK8- andAU1-ERR-positive nuclei, each bar represents the average S.D. of
three independent experiments counted by different operators. TFX, transfection.
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panels, LMB induced nuclear compartmentalization of the
otherwise predominantly cytoplasmic ERK8 protein, sug-
gesting the existence of an active, CRM1-dependent mecha-
nism of ERK8 nuclear export. As expected, LMB did not
perturb the already nuclear localization of ERR (Fig. 3B, left
panels).
We next wished to determine whether CRM1 mediates
ERK8-dependent nuclear export of ERR. As depicted in Fig.
ERK8 as an ERR Corepressor
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3C, left panels,upper row, ERRwas predominantly localized in
the nucleus in HeLa cells not expressing ERK8, whereas cells
co-expressing this MAP kinase showed ERR localization to
the cytoplasm, in line with our previous observations in 293T
cells. However, treating HeLa cells with LMB, ERR localiza-
tion was completely restrained to the nucleus, despite ERK8
co-expression (Fig. 3C, left panels, lower row), definitively sug-
gesting CRM1 involvement in ERR nuclear exclusion induced
by ERK8. As an additional confirmation to these observations
and to obtain quantitative data, we counted the number of
ERK8-positive nuclei from cells expressing only ERK8 (Fig. 3A,
right panel), of ERR-positive nuclei from cells expressing only
ERR (Fig. 3B, right panel) and of ERR-positive nuclei from
cells expressing both ERR and ERK8 (Fig. 3C, right panel), in
the presence or absence of LMB. As expected, in all cases LMB
treatment led to an almost complete re-localization of both
ERK8 andERR to the nucleus.Altogether, these data therefore
allow us to conclude that ERK8 re-localizes ERR to the cyto-
plasm through a CRM1-dependent mechanism.
ERK8 Inhibits ERR Transcriptional Activity—Based on the
previously described data and on ERK8 ability to control the
activity of different nuclear receptors (9, 10), we next asked
whether thisMAPkinasewas able tomodulate ERR transcrip-
tional activity. It is known that ERR and ER can interact in
vitro and induce transcription through both the classical ERE
and the ERR response element (ERRE/SFRE) (15, 33). To
avoid potential biases due to cross-talk between ERR and ER,
we therefore decided to use the ER-negative HeLa cells, a typ-
ical model system used for functional studies on ERR tran-
scriptional activity (37, 38).
To investigate the transcriptional activity of this nuclear
receptor, we used a firefly luciferase reporter vector, ERRE_Luc,
in which the luciferase gene is under control of a minimal pro-
moter harboring three ERRE/SFRE repeats (16). As expected
(16), the activity of the reporter was dependent on ERR
expression (Fig. 4A). Next, we studied the effect of ERK8 on
ERR transcriptional activity by co-transfecting, together with
the ERRE_Luc reporter, an ERR expression vector alone or in
combinationwith the ERK8 expression vector. Luciferase activ-
ity increased3-fold in the presence of ERR but, remarkably,
it returned to basal levels when ERR and ERK8 were co-ex-
pressed (Fig. 4B), therefore indicating a corepressive role for
ERK8 on ERR transcriptional activity. As a control, the
expression of ERK8 alone had no effect on the reporter (Fig.
4B). Furthermore, overexpression of otherMAPkinases such as
JNK could not counteract ERR-dependent induction of the
ERRE_Luc reporter (Fig. 4C). Although ERR was a very poor
inducer of the reporter (39), ERR and ERR activities were not
affected by ERK8 in HeLa cells (supplemental Fig. S1B), con-
firming the specificity of the ERK8 effect on ERR.
Due to the lack of a natural agonist, the induction of ERR
transcriptional activity heavily relies on “proteic coactivators,”
the best characterized of which is PGC1 (40). Therefore, we
sought to determine whether ERK8 could counteract PGC1-
dependent ERR activation as well. Fig. 4D clearly shows that,
despite the remarkable induction of ERR transcriptional
activity by PGC1, ERK8 was still able to inhibit such
activation.
ERR is phosphorylated in vivo on multiple sites (27, 28). It
has been recently reported that some of these phosphorylation
events are responsive to epidermal growth factor receptor
(EGFR) stimulation and are able to enhance ERR binding to
DNA and, therefore, its transcriptional activity (28). As HeLa
cells express high EGFR levels (Fig. 4E), we tested the ability of
ERK8 to interfere with the activity of ERR induced by the EGF
signaling pathway in this experimental model. As shown in Fig.
4F, ERK8 retained its corepressive function onERR evenwhen
this nuclear receptor was activated by EGF. Similarly, ERR
stimulation induced by two human-activated EGFR oncogenic
mutants (EGFR L858R and EGFR D770_N771 insNPG) (41)
was also completely abolished by ERK8 expression (Fig. 4F).
Altogether, our data therefore demonstrate that ERK8 is a bona
fide ERR corepressor, exerting such function in a highly spe-
cific manner on ERR, both on its basal activity and in situa-
tions in which this nuclear receptor is induced by proteic
coactivators, such as PGC1, or by well characterized stimuli,
such as activation of the EGF signaling pathway.
ERK8 Modulates the Expression of ERR Target Genes—
Based on evidence that ERK8 inhibits ERR transcriptional
activity in a luciferase reporter system, we sought to study the
ability of ERK8 to control the endogenous expression of ERR
transcriptional targets as well. To this purpose, ERK8 expres-
sion was silenced in HeLa cells using a validated (5) siRNA to
score, by real time PCR, the effects of ERK8 depletion on the
expression levels of two well established ERR target genes,
CYP11A1 and CYP27A1 (42). In these conditions, whereas
ERK8 mRNA levels underwent a 50% reduction (Fig. 5A) we
observed a 2- and 2.5-fold increase in CYP11A1 (Fig. 5B)
and CYP27A1 mRNA expression (Fig. 5C), respectively. As a
control, ERK8mRNAdepletion had no effect on the expression
of a gene whose expression does not depend on ERR, namely
ERK2 (Fig. 5D). These data therefore support our previous
FIGURE3.CRM1-dependentcytoplasmic localizationofERR inducedbyERK8, inHeLacells.A, left panels, confocalmicroscopy imagesof cells transfected
with HA-ERK8 (300 ng), left untreated (top row), or treatedwith 5 nM LMB for 24 h (bottom row). Cells were incubatedwith anti-ERK8 antibody and labeledwith
Cy2-conjugated secondary antibody and DAPI for nuclear staining. A, right panel, increase in the number of 293T cells with HA-ERK8-positive nuclei after
treatment with LMB. 293T cells were transfected, treated, and labeled as in A, left panels, then cells with HA-ERK8-positive nuclei were counted in 20 random
fields. B, left panels, confocalmicroscopy images of cells transfectedwith AU1-ERR (300 ng), left untreated (top row), or treatedwith 5 nM LMB for 24 h (bottom
row). Cellswere incubatedwithanti-AU1antibodyand labeledwithTRITC-conjugated secondary antibodyandDAPI fornuclear staining.B, right panel, increase
in the number of 293T cells with AU1-ERR-positive nuclei after treatment with LMB. 293T cells were transfected, treated, and labeled as in B, left panels, then
cellswithAU1-ERR-positivenucleiwere counted in20 randomfields.C, left panels, confocalmicroscopy imagesof cells co-transfectedwithAU1-ERR (300ng)
andHA-ERK8 (300ng), left untreated (top row), or treatedwith5nMLMB for 24h (bottom row). Cellswere incubatedwith anti-AU1andanti-ERK8antibodies and
labeled with TRITC- and Cy2-conjugated secondary antibodies. C, right panel, increase in the number of ERK8-transfected 293T cells with AU1-ERR-positive
nuclei after treatment with LMB. 293T cells were transfected, treated, and labeled as in C, left panels, then cells with AU1-ERR-positive nuclei were counted in
20 random fields. In all experiments involving the count of HA-ERK8- and AU1-ERR-positive nuclei, each bar represents the average S.D. of three indepen-
dent experiments counted by different operators. TFX, transfection.
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observations and confirm the role of ERK8 inmodulating ERR
transcriptional activity, in vivo.
ERK8 Binds to ERR through LXXLL Motifs Typical of Ago-
nist-bound Nuclear Receptor Corepressors—Interactions of
nuclear receptors with coregulatory proteins are mediated by
conserved motifs, well defined for both coactivators and core-
pressors. Classical corepressors, which prevent unliganded
nuclear receptors from being activated by ligands, are charac-
terized by the “corepressor nuclear receptor” (CoRNR) box,
typically having a sequence of (L/V)XX(I/V)I or alternatively
LXXX(I/L)XXX(I/L) (where L is leucine, V is valine, I is isoleu-
cine, and X is any amino acid) (43). Ligand binding favors the
displacement of this kind of corepressors and the recruitment
of coactivators, characterized instead by the LXXLL box (44).
Still, a different family of corepressors that are able to inhibit
active, ligand-bound, nuclear receptors through an LXXLL box,
hence named “agonist-bound nuclear receptor corepressors,”
has been recently described (45).
In silico analysis of the ERK8 protein sequence led us to iden-
tify two putative LXXLL boxes starting at amino acids 265 and
281, respectively (referred to as LXXLL Box 1 and LXXLL Box 2
herein), in the C-terminal domain of ERK8. Of note, the two
putative LXXLL boxes appeared to be very well conserved
among different species (Fig. 6A), the conservation of this par-
ticular structuralmotif being suggestive of its importance in the
function of ERK8, otherwise exhibiting very low homologywith
its orthologs, especially in its C-terminal domain (3). Hence, to
investigate whether the two LXXLL boxes are involved in the
interaction with ERR, we generated ERK8 mutants in which
we substituted leucine residues with alanines in LXXLL Box 1
(ERK8 3LA1 mutant), in LXXLL Box 2 (ERK8 3LA2), and in
both (ERK8 3LA1–2), respectively. As shown in Fig. 6B, inter-
action of thesemutants with ERRwas barely detectable. Next,
based on the ability of ERK8 to prevent nuclear localization of
ERR (see above), we wanted to determine whether the LXXLL
mutants, whose interaction with ERR is hindered, could still
affect the subcellular localization of this nuclear receptor. As
shown in Fig. 6C, the ERK8 LXXLL mutants, whereas showing
the same localization of wild-type ERK8 (middle row), lost the
ability to re-localize ERR to the cytoplasm. Biochemical frac-
tionation in Fig. 6D also confirmed the increase of ERR in the
cytoplasm in the presence of wild-type ERK8 as well as the
inability of the ERK8 LXXLL mutants to efficiently promote
the nuclear export of ERR. Accordingly, 293T cells transfected
with the nuclear receptor showed a more modest decrease in
the number of ERR-positive nuclei when co-expressing the
ERK8 LXXLL mutants, compared with cells co-expressing the
wild-type ERK8 (Fig. 6E). Next, to ascertain whether the inter-
action between these two proteins is necessary for ERK8 core-
pressive function, we tested the ERK8 LXXLLmutants for their
ability to inhibit ERR transcriptional activity. We therefore
co-transfected the ERRE_Luc reporter vector along with ERR
and either wild-type ERK8 or the different mutants. Fig. 6F
clearly shows that all ERK8 mutants lost the ability to repress
ERR transcriptional activity, thus supporting the conclusion
that the LXXLL boxes are essential for ERK8 corepressive
function.
Altogether, our data identify two LXXLLmotifs contained in
the ERK8 C-terminal domain as necessary features for ERK8 to
interact with ERR, to regulate its subcellular localization and
to inhibit its transcriptional activity. Based on previous data
indicating ERR as a constitutively active nuclear receptor (18),
such features also suggest ERK8 as a newmember of the family
of agonist-bound nuclear receptor corepressors, unique in its
ability to control the functions of orphan members of this fam-
ily of proteins, whose structure is already locked in a transcrip-
tionally active conformation, even in the absence of a natural
ligand.
ERK8 Negatively Regulates Endogenous ERR Activity and
Controls Its Cellular Localization, in Human Breast Epithelial
Cells—Next, we decided to evaluate the effect of ERK8 on
endogenous ERR, in a biologically relevant cellular system, the
human immortalized mammary epithelial MCF10A cell line.
These cells are in fact often used to recapitulate differentiation
and transformation of the human breast epithelium (46, 47), a
tissuewhosemalignant proliferation is indeed affected byERR
FIGURE4.Effect of ERK8onERR transcriptional activity inHeLa cells.A, activationof ERRE_Luc luciferase reporter vector after transfectionwith increasing
concentrations of AU1-ERR expression vector, as indicated; 20 l of the same cellular lysate was subjected to Western blot (WB) with anti-ERR antibody.
B, AU1-ERR-induced ERRE_Luc luciferase reporter activity is inhibited by HA-ERK8; 20 l of the same cellular lysate was subjected to Western blot with
anti-ERR and anti-ERK8 antibodies.C, AU1-ERR-induced ERRE_Luc luciferase reporter activity is not inhibitedbyHA-JNK; 20l of the same cellular lysatewas
subjected to Western blot with anti-ERR and anti-HA antibodies. D, HA-ERK8 inhibits AU1-ERR-induced ERRE_Luc luciferase reporter activity following
stimulation of AU1-ERRwith myc-tagged PGC1; 20 l of the same cellular lysate was subjected to Western blot with anti-ERR, anti-ERK8, and anti-PGC1
antibodies. E, expression levels of endogenous EGFR. Cellular lysates (30 g) from 293T, HeLa, and MCF10A cells were subjected to SDS-PAGE followed by
Western blot with anti-EGFR and anti-Actin antibodies. F, HA-ERK8 inhibits AU1-ERR-induced ERRE_Luc luciferase reporter activity following stimulation of
AU1-ERR with EGF (100 g/ml, 4 h) or transfection with two constitutively active mutants of EGFR (EGFR L858R and EGFR D770_N771 insNPG); 20 l of the
same cellular lysate was subjected to Western blot with anti-ERR and anti-ERK8 antibodies. RLU, relative light units.
FIGURE 5. Effect of ERK8 knockdown on the expression of ERR target
genes. Expression levels of ERK8 (A), CYP11A1 (B), CYP27A1 (C), and ERK2 (D)
mRNAs 48 h after scramble (scr) or ERK8-specific siRNA transfection.
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(22, 23, 26). Importantly, MCF10A cells express high levels of
ERR but no ER (Fig. 7A and Ref. 9), allowing us to avoid
possible biases due to cross-talk between ERR and ER (see
above). Therefore, we first confirmed in these mammary epi-
thelial cells our findings obtained in 293T and HeLa, by show-
ing that ERK8 induced the cytoplasmic re-localization (Fig. 7B)
and inhibited the transcriptional activity (Fig. 7C) of ectopically
expressed ERR. Next, to determine whether our reporter
assay was able to detect the signal generated by the endogenous
ERR, we treated ERRE_Luc-transfected MCF10A cells with
the ERR-specific inverse agonist XCT790. As a result of drug
action on both ERR transactivation potential and protein lev-
els (25), the activity of the luciferase reporter underwent a
markeddose-dependent decrease, thus indicating that the basal
ERRE_Luc luciferase signal observed inMCF10A is mostly due
to endogenous ERR (Fig. 7D). Based on this information, we
observed a highly significant decrease in the ERRE_Luc
reporter activity in MCF10A cells transfected with ERK8, indi-
cating that ERK8 can indeed inhibit the transcriptional activity
of endogenous ERR (Fig. 7E). Next, based on the ability of
ERK8 to prevent nuclear localization of exogenously expressed
ERR, we wanted to determine whether thisMAP kinase could
also affect the subcellular localization of the endogenous
nuclear receptor. Indeed, as shown in Fig. 7F, only MCF10A
cells expressing ERK8 showed cytoplasmic localization of the
ERR protein. In line with this observation, cell fractionation
experiments showed a clear increase of ERR levels in the cyto-
plasmic fraction of MCF10A cells stably expressing the ERK8
protein (Fig. 7G, left panels). As MCF10A cells also express
endogenous ERK8 (8, 9), we next confirmed the interaction
between endogenous ERK8 and ERR proteins. Indeed, in line
with our results on ectopically expressed proteins (Figs. 1C and
6B), endogenous ERK8 evidently co-immunoprecipitated in
vivo with endogenous ERR (Fig. 7H). Ultimately, we set up to
evaluate the ability of ERK8 to counteract activation of endog-
enous ERR by stimuli relevant for breast cancer, e.g. activation
of the EGFRpathway (48). To this aim, asMCF10Acells express
very low levels of EGFR (see Fig. 4E), we decided to overexpress
in these cells the constitutively active EGFR mutants, EGFR
L858R and EGFR D770_N771 insNPG, which, although typi-
cally found in non-small cells lung carcinomas (41), well reca-
pitulate activation of the EGFR pathway in human cancer. In
agreement with our findings in HeLa cells (see Fig. 4F), activa-
tion of the EGFR signaling pathway inMCF10A cells increased
the activity of endogenous ERR, whereas ERK8 retained its
repressory effect even on the endogenous nuclear receptor
stimulated by EGFR-derived activated oncogenes (Fig. 7I).
These results therefore propose ERK8 as a corepressor of
endogenous ERR, with the ability to promote its cytoplasmic
localization and counteract its activation by positive cellular
stimuli often deregulated in human cancers.
DISCUSSION
In this paper we demonstrate that ERK8, a member of the
MAP kinase family of proteins, is a bona fide ERR corepressor,
able tomodulate the subcellular localization and activity of this
nuclear receptor. Indeed, our data support a model in which
ERK8 binds to ERR, inhibits both its basal and stimulated (by
PGC1 and the EGFR pathway) activity, and induces its local-
ization to the cytoplasm (Fig. 8).
Recent work has already revealed that ERK8 negatively reg-
ulates the activity of androgen and glucocorticoid receptors by
interacting with the HIC-5 coactivator (10), and that the prod-
uct of its murine ortholog gene enhances the degradation of
ER (9). However, differently from what was demonstrated for
these nuclear receptors, we show a direct interaction between
ERK8 and ERR. Also, unlike ER, we observed no decrease in
the protein levels of ERR in the presence of ERK8. Therefore,
it appears that ERK8 is amultifunctional corepressor for differ-
ent nuclear receptors. Still, its corepressive activity is certainly
not aspecific, as we demonstrate that it is able to discriminate
among very similar proteins such as different members of the
ERR subfamily. In this context, it is worth noting that ERK8 is
able to influence the expression of ERR target genes such as
CYP11A1 and CYP27A1 (42). Interestingly, CYP11A1 encodes
for the cholesterol side chain cleavage enzyme (P450scc), which
mediates the initial and rate-limiting step in steroidogenesis,
converting cholesterol to pregnenolone, the precursor of
androgens, estrogens, and progesterone, and which has been
heavily associated to prostate (49), breast (50), and endometrial
(51) cancer risk. On the other hand, CYP27A1 encodes for ste-
rol 27-hydroxylase, a cytochrome P450 family member impli-
cated in the metabolism of vitamin D. Overall, the presence of
ERK8 may therefore coordinately modulate, by multiple and
different mechanisms, the activity of several nuclear receptors,
at multiple levels, possibly in response to specific cellular
stimuli.
Coregulatory proteins are key modulators of nuclear recep-
tor-dependent transcription of target genes (52). In nuclear
receptors, in fact, helix 12 (also referred to as activation func-
FIGURE 6. The LXXLL motifs of ERK8 are necessary for its ability to control ERR cellular localization and its corepressor activity. A, schematic repre-
sentation of the ERK8 protein, showing the position of the two identified LXXLLmotifs, and sequence alignment of the region of ERK8 flanking the two LXXLL
motifs (boxed) in various species. B, in vivo GST pulldown to test the interaction of ERR with the ERK8 LXXLL mutants. 293T cells were co-transfected with
GST-ERR (1g) andHA-ERK8 (1g) or ERK8mutants (1g) on the first (3LA1), second (3LA2), or both LXXLLmotifs (3LA1–2). Cellular lysateswere pulled down
withglutathione-Sepharosebeads 4B (3h at 4 °C) andanalyzedbyWesternblot (WB)with anti-ERK8 antibody (top). 293T total cellular lysateswereblottedwith
anti-ERK8 (middle top), anti-ERR (middle bottom), and anti-ERK2 (bottom) antibodies for normalization purposes. C, confocal microscopy images of 293T cells
co-transfected with AU1-ERR and HA-ERK8 (left), HA-ERK8 3LA1 (middle left), HA-ERK8 3LA2 (middle right), or HA-ERK8 3LA1–2 (right). Cells were incubated
with anti-AU1andanti-ERK8antibodies and labeledwith TRITC- andCy2-conjugated secondary antibodies.D, HA-ERK8expression (left), but notHA-ERK83LA1
(middle) orHA-ERK83LA2expression (right), increases theamountofAU1-ERR in the cytoplasmic fractionofHeLa cells. HeLa transfectedwithAU1-ERRalong
with EGFP, HA-ERK8, HA-ERK8 3LA1, or HA-ERK8 3LA2 (1 106 cells) were subjected to fractionation using the Subcellular Protein Fractionation Kit (Thermo
Scientific); lysateswere subjected toSDS-PAGE followedbyWesternblotwith anti-ERR (top), anti-ERK8 (middle top), anti-IB (middle bottom), andanti-Lamin
A/C (bottom) antibodies. E, decrease in the number of 293T cellswithAU1-ERR-positive nuclei in the presence of HA-ERK8, but not in the presence of the ERK8
LXXLLmutants. Cells were transfected and labeled as in C, then cells with AU1-ERR-positive nuclei were counted in 20 random fields; each bar represents the
average S.D. of three independent experiments countedby different operators. F, ERK8 LXXLLmutants fail to inhibit AU1-ERR-induced ERRE_Luc luciferase
reporter activity; 20 l of the same cellular lysate used for the luciferase assay was subjected to Western blot with anti-ERR and anti-ERK8 antibodies.
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tion 2) is critical in determining which kind of coregulator
docks. Inactive nuclear receptors, unbound to ligands, have
helix 12/activation function 2 in a conformation that provides
access to corepressors interacting via the so-called corepressor
nuclear receptor box (52), typically having a sequence of
(L/V)XX(I/V)I or LXXX(I/L)XXX(I/L) (53). Upon agonist bind-
ing, helix 12/activation function 2 is repositioned in a confor-
mation that no longer allows interaction of the corepressor
nuclear receptor box with the corepressor-binding area,
although favoring the interaction with coactivator boxes, typi-
cally having an LXXLL sequence (52). Therefore, typical core-
pressors lack the structural means to repress agonist-bound,
active nuclear receptors. This model was initially challenged by
the discovery of receptor interacting protein 140 (RIP140),
which has the structural features of a coactivator, and included
LXXLL sequences determining the interaction with the recep-
tors, but acts as a corepressor (45). The discovery of a fewmore
such coregulators gave rise to a small family of agonist-depen-
dent corepressors whose interaction with activated nuclear
receptors depends on LXXLL boxes (54). Moreover, ERR,
even if not bound to any ligand, is constitutively active and
arranged in a structure typical of ligand-bound receptors (18).
It is therefore not surprising for us to find two functional
LXXLLmotifs in ERK8mediating its corepressive functions on
ERR. Together, these data led us to the conclusion that ERK8
is the first representative of a new class of corepressors that are
able to control, through LXXLL boxes, the functions of orphan
nuclear receptors whose structure is already locked in a tran-
scriptionally active conformation, even in the absence of a nat-
ural ligand. In this context it is important to note that the two
LXXLL boxes of ERK8 are perfectly conserved inmammals and
birds, five of the six leucines are conserved in zebrafish, and the
LXXLL box 2 is perfectly conserved down to Drosophila mela-
nogaster (data not shown). Such remarkable conservation
FIGURE 7. ERK8-dependent cytoplasmic re-localization of endogenous ERR and inhibition of its transcriptional activity, in MCF10A cells. A, expres-
sion levels of endogenous ERR in our experimental cellular models. Total cellular lysates (30 g) from 293T, HeLa, and MCF10A cells were subjected to
SDS-PAGE followed by Western blot (WB) with anti-ERR and anti-Actin antibodies. B, confocal microscopy images of MCF10A cells co-transfected with
AU1-ERR (500 ng) and HA-ERK8 (1 g), then incubated with anti-AU1 and anti-ERK8 antibodies and labeled with TRITC- and Cy2-conjugated secondary
antibodies. C, ERR-induced ERRE_Luc luciferase reporter activity is inhibited by HA-ERK8 in MCF10A cells; 20 l of the same cellular lysate was subjected to
Western blot with anti-ERR and anti-ERK8 antibodies.D, ERRE_Luc basal activity inMCF10A cells is due to the transactivation potential of endogenous ERR.
MCF10A cells were transfected with the ERRE_Luc luciferase reporter vector and treated with 10 or 20 M XCT790; after 24 h, cells were lysed and assayed for
luciferase activity; 20 l of the same cellular lysate was subjected to Western blot with anti-ERR antibody. E, HA-ERK8 inhibits ERRE_Luc luciferase reporter
activity induced by endogenous ERR in MCF10A cells (***, p 0.001 according to unpaired Student’s t test); 20l of the same cellular lysates was subjected
to Western blot with anti-ERR and anti-ERK8 antibodies; F, confocal microscopy images of MCF10A cells transfected with HA-ERK8 (1.5 g), then incubated
with anti-ERR and anti-HA antibodies and labeled with TRITC- and Cy2-conjugated secondary antibodies and DAPI for nuclear staining. G, ERK8 expression
increases the amount of ERR in the cytoplasmic fraction of MCF10A cells; MCF10A stably expressing EGFP or HA-ERK8 (5  106 cells) were subjected to
fractionation using the Subcellular Protein Fractionation Kit (Thermo Scientific); lysates were subjected to SDS-PAGE followed byWestern blot with anti-ERR
(top), anti-ERK8 (middle top), anti-IkB (middle bottom), and anti-Lamin A/C (bottom) antibodies;H, interaction between endogenous ERK8 and ERR proteins;
total cellular lysate (1 mg) from MCF10A cells was subjected to immunoprecipitation with anti-ERR antibody or with rabbit preimmune serum (4 h at 4 °C),
then subjected to SDS-PAGE and blotted with anti-ERK8 antibody (Kinasource) (top). Total cellular lysates (50 g) were blotted with anti-ERK8 (middle) and
anti-ERR (bottom) antibodies for normalization purposes. I, HA-ERK8 inhibits ERRE_Luc luciferase reporter activity induced by endogenous ERR following
stimulationof thenuclear receptorwith twoconstitutively activemutants of EGFR (EGFRL858RandEGFRD770_N771 insNPG); 20l of the samecellular lysates
was subjected to Western blot with anti-ERR and anti-ERK8 antibodies.
FIGURE 8.Mechanism of ERK8 action on ERR. ERR is a constitutively active orphan nuclear receptor whose activity can be further increased by proteic
coactivators (PGC1) (40) or EGFR-dependent signaling (27, 28). ERK8 acts as a bona fide ERR-specific corepressor interacting with the nuclear receptor
through its LXXLL motifs and promoting its re-localization from the nucleus to the cytoplasm.
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appears evenmore relevant when comparedwith the otherwise
extremely low conservation score of the ERK8 protein through-
out evolution.
Subcellular localization and dynamic movements between
cellular compartments are importantmechanisms used by cells
to regulate the activity of different transcription factors (55). As
concerns nuclear receptors, several groups have demonstrated
that they continuously shuttle between the cytoplasm and the
nucleus, as a consequence of a fine balance between operational
strengths of nuclear localization signals and nuclear export sig-
nals (55, 56). The subcellular compartmentalization and the
timely and efficient localization of these transcription factors
are usually modulated through the binding of specific ligands,
such as steroid or thyroid hormones (55). In principle, all
nuclear receptors, when bound to their natural ligands, trans-
locate to the nucleus and become transcriptionally active, being
the nuclear localization necessary for their direct action on tar-
get genes. On the other hand, unliganded, inactive receptors
appear to have a more diverse localization pattern, from pre-
dominantly cytoplasmic to uniformly distributed between the
cytoplasm and nucleus (57–59) to predominantly nuclear (60–
62). Moreover, steroid receptor localization has also been
extended to mitochondria (63, 64) and plasma membrane (65–
67). Interestingly, some nuclear receptors, such as the ER,
have even higher complexity, requiring a cytoplasmic localiza-
tion, evenwhen ligand-bound and active, to exert specific “non-
genomic” functions alternative to direct promoter binding and
necessary for cellular transformation (35). As mutations of
ERK8 that prevent interaction also abolish its corepressive
functions and ERR cytoplasmic localization, we can state that
direct interaction is a prerequisite for inhibition of ERR activ-
ity aswell as for its nuclear exclusion.However, the relationship
between ERR activity and cytoplasmic localization needs fur-
ther investigation. Indeed, whereas ERR nuclear exclusion
prevents the interaction of this nuclear receptor with the
promoters of its target genes and therefore may participate
to the inhibition of its constitutive transcriptional activity,
we cannot exclude that ERR may also control, in the cyto-
plasm, alternative, non-genomic functions contributing to
its biological activity, as described for ER (35, 68, 69) and
progesterone receptor (70). In this context, it is important to
note that a naturally occurring short form of the metastatic
tumor antigen 1 (MTA1s) is a characterized ER corepressor
that sequesters this steroid receptor to the cytoplasm
through an LXXLL motif, enhancing non-genomic functions
such as ERK2 activation (71). The analogies between the
short form of the metastatic tumor antigen 1-ER and the
ERK8-ERR situations may therefore suggest that ERK8,
whereas negatively regulating ERR transcriptional activity,
may control as yet to be described non-genomic functions of
this protein by regulating its nucleocytoplasmic shuttling.
Further work will be required to establish the precise func-
tions exerted by ERR in the cytoplasm as well as the role of
ERK8 in controlling such activities.
In addition to its physiological functions in cellular metab-
olism and in responses to stressors requiring shifts in energy
production and utilization (12, 13, 72, 73), an increasingly
important role for ERR in humanmalignancies is emerging.
Silencing of ERR and the use of specific pharmacological
inhibitors suggest a critical role for this nuclear receptor in
the growth of highly aggressive forms of breast cancer (22–
25). Moreover, it is known that ERR and ER can interact in
vitro and regulate transcription through the classical ERE
(15, 33), and that ERR behaves as a repressor or an activator
of ER-regulated transcription in a cell type-dependent man-
ner (74). Hence, it has been proposed that, whereas ERR
tightly regulates estrogen responsiveness in normal breast
cells, it may functionally replace ER in ER-negative breast
tumors, thereby constitutively activating ERE-regulated
transcription (74). Thus, the conversion of ERR from a
repressor to an activator may be a critical step in the progres-
sion of breast tumors to a hormone-independent phenotype,
suggesting that ERK8 may provide opportunities for novel
therapeutic approaches for the treatments of these tumors.
Evidences are accumulating about the involvement of ERK8
in human cancer (7, 9). In the context of breast cancer, in par-
ticular, highERK8 expressionhas beendemonstrated in normal
human mammary cells, whereas loss of its expression has been
correlated with breast cancer progression and increased ER
levels (9). Our findings therefore suggest that, in breast, ERK8
may participate in maintaining tissue homeostasis not only by
regulating ER protein degradation (9) but also by controlling
the activity and cellular localization of ERR, whose role in
cellular metabolism and transformation has now been well
established (28, 75, 76). Hence, this MAP kinase might regulate
estrogen transcriptional targets both directly, by enhancing
ER degradation, and indirectly, by modulating the physical
and functional interactions of this nuclear receptor with ERR.
Based on the well established role of estrogens in breast cancer
progression, through the expression of cellular proto-onco-
genes (e.g. c-MYC) aswell as extracellularmatrixmolecules (e.g.
syndecan-2 and metalloproteinase-9) (77, 78), the ability of
ERK8 to control and integrate signals from ER and ERR
receptors in normal and transformed mammary cells warrants
further investigation.
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